Close
Help
Need Help?



Preliminary Study and Improve the Production of Metabolites with Antifungal Activity by A Bacillus Sp Strain IBA 33

Submit a Paper


Libertas Analytics


1411 Article Views

Publication Date: 08 Apr 2009

Journal: Microbiology Insights 2009:2 15-24

MI
journal

22,807 Article Views

3,056,940 Libertas Article Views

More Statistics

Abstract Bacillus sp strain IBA 33 metabolites, isolated from decaying lemon fruits, were evaluated for the control of pathogenic and non-pathogenic fungi (Penicillium digitatum, Geotrichum candidum, Penicillium expansum, Aspergillus clavatus, Aspergillus flavus, Aspergillus niger, and Fusarium moniliforme). These metabolites were recovered from Landy medium (LM) without aminoacids. In order to optimize metabolites production the LM was modified by adding different concentrations and sources of amino acids and carbohydrates at different culture conditions. Bacillus sp strain IBA 33 metabolites efficacy to control fungi were evaluated with in vitro and in vivo assays. A. flavus growth inhibition was 52% with the metabolites of Bacillus sp strain IBA 33 recovered from LM (MBLM) in vitro assays. MBLM supplemented with 0.5% glutamic acid, inhibited the growth of P. digitatum, G. candidum, A. clavatus, A. niger and F. moniliforme by 65%, 88.44%, 84%, 34% and 92% respectively. The highest inhibition of P. expansum was 45% with MBLM supplemented with 0.5% aspartic acid. Similar results were obtained in vivo assays. These results showed that Bacillus sp strain IBA 33 metabolites specificity against fungi depended on the composition of the LM.


Post a Comment

x close

Discussion Add A Comment
No comments yet...Be the first to comment.


share on

Our Service Promise

  • Prompt Processing (Average 3 Weeks)
  • Fair & Constructive Peer Review
  • Professional Author Service
  • High Visibility
  • High Readership
  • What Our Authors Say

Quick Links

Follow Us We make it easy to find new research papers. RSS Feeds Email Alerts Twitter

BROWSE CATEGORIES
Our Testimonials
The publishing experience in Libertas Academica journals is unique. Readers can feel satisfied that publications are peer reviewed. Authors follow simple steps to reach final stage of publication. All readers have access to articles. Journal subscriptions or medical library access is not needed.
Dr Akram Al Hilali (Consultant Hematopathologist, Dubai Health Auhority, Dubai) What our authors say